Serious adverse events (number) · participants with severe alcoholic hepatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (6 months · children with stable wrist fracture, predominantly buckle (torus) fracturesa
1 finding from 1 review
Serious adverse events (6 months · children with stable wrist fracture, predominantly buckle (torus) fracturesa
1 finding from 1 review
Serious adverse events (12 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).
1 finding from 1 review
Adverse events: serious infections · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor showed no clear difference in adverse events: serious infections compared with IV cyclophosphamide (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (proportion) · people with acute pancreatitis
It is very uncertain whether the intervention changes serious adverse events (proportion) (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether bile acids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · participants with severe alcoholic hepatitis
It is very uncertain whether glucocorticosteroids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether glucocorticosteroids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review